PARADIGM-2:OlaPArib and RADIotherapy or olaparib and radiotherapy plus temozolomide in newly-diagnosed Glioblastoma stratified by MGMT status: 2 parallel phase I studies
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms PARADIGM-2
- 04 Sep 2017 Planned End Date changed from 31 Jan 2019 to 31 Dec 2020.
- 13 Jul 2016 Status changed from not yet recruiting to recruiting.
- 22 Jun 2016 New trial record